Please login to the form below

axitinib

This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.

Keytruda shows significant and meaningfully improvement in kidney cancer

has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma. ... Keytruda is currently approved in the US, Europe and Japan in combination with axitinib for the first-line treatment of

Latest news

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Both Opdivo combinations will compete with Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib), after the combination treatment received FDA approval in the same
Pfizer, Sanofi and others set to increase US drug prices in 2021

drugs Ibrance (palbociclib) and Inlyta (axitinib).
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Merck already has approval for another combination treatment, Keytruda plus Inlyta (axitinib), for the first-line treatment of advanced RCC.
BMS eyes approval for second Opdivo combo in kidney cancer

However, it has been facing competition from Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib) after the combination treatment won US Food and Drug
NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most

More from news
Approximately 5 fully matching, plus 39 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Principal Medical Writer: Varies on experience

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Content Editor - Biotechnology: Salary TBC

Account Management: Competitive Salary Offered

PMHub

Add my company

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...